LB Pharmaceuticals Cash Flow Statement
NASDAQ: LBRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
37.22+2.61 (+7.54%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
LB Pharmaceuticals free cash flow
In fiscal 2025, LB Pharmaceuticals generated -$35.2 million of operating cash flow and spent $52,000 on capital expenditures. That left free cash flow of -$35.3 million.
Summary generated from market data by MetaCap's automated system. Methodology
LB Pharmaceuticals cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 |
|---|---|---|
| Net Income | -25.20M | -63.10M |
| Net Income growth (YoY) | — | — |
| Depreciation & Amortization | 321.00K | 91.00K |
| Stock-Based Compensation | 4.19M | 3.09M |
| Change in Working Capital | -13.25M | 3.26M |
| Operating Cash Flow | -35.21M | -53.05M |
| Capital Expenditures | -52.00K | -769.00K |
| Investing Cash Flow | -39.89M | 23.23M |
| Financing Cash Flow | 302.56M | 38.31M |
| Net Change in Cash | 227.47M | 8.50M |
| Free Cash Flow | -35.26M | -53.82M |
This table shows 2 annual periods of LB Pharmaceuticals's cash flow statement, from FY 2025 back to FY 2024, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow LBRX's reporting calendar. What is a cash flow statement?